Regencell Bioscience Holdings annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Regencell Bioscience Holdings R&D Spending Growth & History (RGC)
Regencell Bioscience Holdings's r&d spending was $948,289 for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $948,289 | −$117,944 | −11.06% |
| 2024 | 2024-06-30 | $1.1M | −$515,395 | −32.59% |
| 2023 | 2023-06-30 | $1.6M | −$930,526 | −37.04% |
| 2022 | 2022-06-30 | $2.5M | $2.1M | +473.13% |
| 2021 | 2021-06-30 | $438,323 | $52,093 | +13.49% |
| 2020 | 2020-06-30 | $386,230 | $158,007 | +69.23% |
| 2019 | 2019-06-30 | $228,223 | — | — |
Regencell Bioscience Holdings r&d spending trends
Over the last five fiscal years, Regencell Bioscience Holdings's r&d spending increased from $386,230 to $948,289, a change of $562,059.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings source filings ↗